drugset / Trial / NCT05766748
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
NaSequentialOpen-labelTreatment
Summary
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
Timeline
- Start
- 2023-06-01
- Primary completion
- 2025-02
- Completion
- 2025-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azeliragon | Small molecule | 5 mg | Oral |
| Subject | Azeliragon | Small molecule | 10 mg | Oral |
| Subject | Azeliragon | Small molecule | 15 mg | Oral |
| Subject | Azeliragon | Small molecule | 20 mg | Oral |
| Subject | Azeliragon | Small molecule | 25 mg | Oral |